Disease and Lorazepam


Disease Symptoms and Causes

Creutzfeldt-Jakob Disease (CJD) is a rare, degenerative brain disorder. Symptoms usually start around age 60. Memory problems, behavior changes, vision problems, and poor muscle coordination progress quickly to dementia, coma, and death. Most patients die within a year.

The three main categories of CJD are

  • Sporadic CJD, which occurs for no known reason
  • Hereditary CJD, which runs in families
  • Acquired CJD, which occurs from contact with infected tissue, usually during a medical procedure

Cattle can get a Disease related to CJD called bovine spongiform encephalopathy (BSE) or "mad cow Disease." There is concern that people can get a variant of CJD from eating beef from an infected animal, but there is no direct proof to support this.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for disease

disease treatment research studies

Lorazepam clinical trials, surveys and public health registries

Find Drug Side Effect reports

Lorazepam Side Effects

Completed Suicide (220)
Somnolence (138)
Poisoning (137)
Suicide Attempt (121)
Overdose (105)
Anxiety (104)
Agitation (100)
Tachycardia (84)
Cardiac Arrest (81)
Confusional State (80)
Nausea (79)
Respiratory Arrest (73)
Dizziness (70)
Coma (68)
Sopor (68)
Hypotension (66)
Fall (66)
Toxicity To Various Agents (65)
Intentional Overdose (64)
Dyspnoea (61)
Fatigue (57)
Vomiting (56)
Depression (56)
Insomnia (56)
Cardio-respiratory Arrest (55)
Death (55)
Sedation (52)
Headache (49)
Loss Of Consciousness (48)
Asthenia (45)
Convulsion (45)
Diarrhoea (43)
Metabolic Acidosis (42)
Condition Aggravated (39)
Tremor (37)
Pyrexia (34)
Product Substitution Issue (34)
Unresponsive To Stimuli (34)
Suicidal Ideation (33)
Psychotic Disorder (33)
Feeling Abnormal (33)
Catatonia (33)
Pain (33)
Gait Disturbance (32)
Disorientation (31)
Respiratory Failure (31)
Syncope (30)
Malaise (30)
Depressed Level Of Consciousness (29)
Oxygen Saturation Decreased (29)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews


<strong></strong><span style='color: #808080;'>i rescued a stray cat and last night it was on my lap and decided to claw me while i moved with a sudden turn she was so stuck on me i had to pull her claws off . i have five

A relative is suffering from heart valveleakage with 25% heart efficiency


Do i have PID? i have been experiencing pain in the lower abdomen and pelvic area and some lower back pain...this has been going on on and off from a year now. I also get some white/sometimes yellow or pink discharge every the point that i ha

Feeling apathetic, lack of interest in anything. Not sure if it is my emotional state or because of lorazepam

Hi Yesterday my family was invited to a party and my 10 year old daughter who has Celiac disease ate a few items that I was told was gluten free. She woke up this morning with terrible pains in her stomach and was in the bathroom for quite awhile

Hi I'm Justice, My gf is wonderful n lovely, but recently she kept complaining of vaginal pains when having sexual intercourse and even says she could feel there's some sought of growth going on in her vaginal, I mean bump which she make me feel it

Hi, My daughter is 4 years old and has KAWASAKI DISEASE. She has had her first IVIG treatment and since the treatment her symtoms have reduced or went away which is a wonderful thing. She for the last 24 hrs since the treatment has not had a fever

Hi, My niece is suffering from KAWASAKI DISEASE. When She was 8 month baby she had KAWASAKI that time she was treated with the IVIG and the took aspirin for 4 months.and she was OK for 4 month . now in 5 month again this disease affect

A flu epidemic at a boarding school would be a concern for the Centers for Disease Control true or false?

Why do doctors keep the availabilty of the test for DPD deficiency a secret??? My sister is a doctor, infectious disease, at St Francis in Charleston, SC. Our father was treated by an oncologist well known to my sister, a 'colleague' you might s

I am having cramps, muscle pain, memory loss, I have been on Revlmid for about 1 year. Does anybody else my age have this disease, I am only 46 yr woman.

<b><span style=' padding: 0px; margin: 0px;'>Hi Can any1 tell me why this medicine (Betaserc) people use and if the disease is dangerous....plz tell me on urgent basis...any1 thnx</b>

<strong>I have very high blood pressure, was put on this drug approximately 5 weeks ago. I was on Coozar previous to this. I also take paracetamol x 1 bd, ceres x 1, venlafaxine x 1, omeprazole x 1, aspirin x 1, have Charcot Marie Tooth Disease

55 yo dx with osearthritis and degenative disc disease, prescribed Mobic 15 mg once a day on medication for past year with no problem.For the past 6weeks had gradual onset of facial and extremity edema , esophageal spasm and expir

After becoming very ill, suffering much pain, losing weight and having many sleepless nights i was finally diagnosed with hoshimotos disease, subsequently i have hypothyroidism. I am only talking 50 mg oroxine 3 times a week and 100 mg the other 2 d

As with any drug, you must weigh the benefits vs. the risks. Revlimid is an incredible drug, which controls my myeloplastic disease with deletion 5q

Can gestodene cause continous dizzyness or meniere's disease.

Centuximab has been diseastrous for me. My fingertips bleed and are infected as well as extremely painful to the touch. I have abdominal pains, constipation. What is worse, the CEA count has jumped and the disease has spread at an alarming rate.

Disease Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for Ulcerative Colitis and Crohn's Disease
Conditions: Ulcerative Colitis;   Crohn's Disease
Intervention: Other: Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)
Outcome Measures: Internal validity, scale F-IBDQ;   External validity, questionnaire SF36;   Discriminant ability, Disease activity indexes;   Reliability, Disease outcomes
2 Recruiting Study of Quality of Life in Freeman-Sheldon Syndrome and Related Conditions
Conditions: Arthrogryposis;   Craniofacial Abnormalities;   Posttraumatic Stress Disorder;   Depressive Disorder
Interventions: Other: PTSD Checklist-Specific;   Other: Modified Flanagan Quality of Life Scale;   Other: Center for Epidemiologic Studies Depression Scale;   Other: Functional Enquiry Form;   Other: Strength, Joint ROM, Girth and Length Measurements;   Other: Study Physical Examination;   Other: PTSD, Depression, and FSS-Focused Examination;   Other: Freeman-Sheldon Specific Quality of Life Survey;   Other: Lactate, Glucose, and Adenosine Triphosphate Blood Levels
Outcome Measures: Situational Mental Health in Persons with FSS or Related Condition;   Situational Mental Health in Family and Others Close to a Person with FSS or Related Condition;   Current Survey Correlation with Disorder-Specific Survey for FSS and Related Conditions
3 Recruiting Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease
Conditions: Inflammatory Bowel Disease;   Glycogen Storage Disease Type Ia
Intervention: Other: Glycogen Storage Disease type Ia patients
Outcome Measure: Serologic, genetic and inflammatory markers consistent with inflammatory bowel Disease
4 Recruiting Canadian Fabry Disease Initiative (CFDI) Enzyme Replacement Therapy (ERT) Study
Condition: Fabry Disease
Interventions: Drug: agalsidase alfa (Replagal®) and agalsidase beta (Fabrazyme®);   Drug: Enzyme Replacement Therapy (ERT)
Outcome Measures: (1) To determine the degree to which existing complications of Fabry Disease respond or fail to respond to ERT;;   (2) To establish a national registry which will collect information related to the identification and monitoring of all persons with Fabry Disease in Canada;;   3) To determine the impact of ERT on the development of complications of Fabry Disease in men and women who are on ERT or whose ERT was interrupted;;   4) To identify which of these clinical problems can best predict the outcome of ERT on Fabry Disease.;   5) To identify possible side effects of ERT
5 Recruiting Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
Conditions: Inflammatory Bowel Disease;   Crohn's Disease;   Ulcerative Colitis;   Indeterminate Colitis
Intervention: Behavioral: Home Monitoring
Outcome Measures: Disease Activity;   Quality of Life;   Health Care Utilization
6 Recruiting Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease
Conditions: Crohn's Disease;   Ulcerative Colitis;   Inflammatory Bowel Disease
Outcome Measures: Genotype a cohort of IBD children for 4 NOD2/CARD15 mutations.;   Statistical analysis of phenotype and genotype correlation in a cohort of pediatric Inflammatory Bowel Disease children with or without a family history of Inflammatory Bowel Disease
7 Recruiting Biomarkers of Risk of Parkinson Disease
Conditions: Parkinson Disease;   Autonomic Nervous System Diseases;   Pure Autonomic Failure
Outcome Measures: Diagnosis of Parkinson Disease (PD) based on the characteristic movement disorder in PD, confirmed by Unified Parkinson Disease Rating Scale (UPDRS).;   Brain 6-[18F]fluorodopa-derived radioactivity; cardiac 6-[18F]fluorodopamine-derived radioactivity; CSF neurochemicals; olfactory testing; autonomic function tests; neurobehavioral rating scales.
8 Recruiting Subthalamic Deep Brain Stimulation (DBS) in Parkinson's Disease
Condition: Parkinson's Disease
Interventions: Procedure: Transcranial Magnetic Stimulation (TMS);   Procedure: Motor Physiology Testing
Outcome Measures: Motor Cortex Excitability;   Relation between Unified Parkinson's Disease Rating Scale outcomes and physiological measures;   Transcallosal Pathway Excitability;   Physiological Measures
9 Recruiting UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource
Conditions: Hepato/Renal Fibrocystic Disease;   Autosomal Recessive Polycystic Kidney Disease;   Joubert Syndrome;   Bardet Biedl Syndrome;   Meckel-Gruber Syndrome;   Congenital Hepatic Fibrosis;   Caroli Syndrome;   Oro-Facial-Digital Syndrome Type I;   Nephronophthisis;   Glomerulocystic Kidney Disease
Outcome Measure: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource (Hepato/Renal Fibrocystic Diseases Core Center (UAB HRFDCC))
10 Not yet recruiting Co-LEsions in Alzheimer Disease and Related Disorders
Conditions: Alzheimer's Disease;   Cerebrovascular Disease;   Lewy Body Disease
Intervention: Radiation: SPECT-DaTscan
Outcome Measures: Disability progression;   Neuropsychological inventory;   NeuroPsychiatric inventory;   Clinical/serum markers
11 Recruiting Comparison of Standard and Low Dose CT Enterography for Crohn's Disease
Condition: Crohn's Disease
Intervention: Radiation: CT Enterography
Outcome Measures: Sensitivity of Low Dose and Standard dose CTE for detecting active Crohn's Disease;   Correlation of Fecal Calprotectin with Radiology findings of Crohn's Disease
12 Recruiting Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention: Drug: Albuterol
Outcome Measures: Presence of obstructive or restrictive lung Disease;   Presence of pulmonary hypertension
13 Recruiting Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Conditions: Muscular Dystrophy;   Congenital Muscular Dystrophy;   Fukutin-related Protein Gene;   Limb Girdle;   FKRP Gene;   Childhood Onset LGMD;   Adult Onset LGMD;   POMT1;   POMT2;   POMGnT1;   LARGE;   Alpha Dystroglycan;   Dystroglycanopathy;   Centronuclear;   Multiminicore;   Multicore;   Minicore;   Congenital Fiber Type Disproportion;   Myotubular;   Nemaline;   Congenital Myopathy;   Neuromuscular;   Rigid Spine;   Phenotype-Genotype Correlation;   Cough Assisted Device;   Neuromuscular Disease;   Respiratory Exacerbation;   Invasive Ventilation;   Chest Physiotherapy;   Congenital Myopathies;   Genetic Mutations;   Hypertrophic Cardiomyopathy;   Wheelchair Use;   Cataract;   Opthalmoplegia;   Ullrich Congenital Muscular Dystrophy;   Intermediate Collagen VI Myopathy;   Laminin Alpha 2 Related Congenital Muscular Dystrophy;   MDC1A;   Merosin Deficient Congenital Muscular Dystrophy;   Congenital Muscular Dystrophy Undiagnosed;   Congenital Muscular Dystrophy Merosin Positive;   Walker Warburg Syndrome;   Muscle Eye Brain Disease;   Fukuyama;   Integrin Alpha 7 Deficiency;   Integrin Alpha 9 Deficiency;   Laminopathy;   Lamin AC;   SEPN 1 Related Myopathies;   Bethlem Myopathy;   Dystroglycanopathies;   LGMD2K;   LGMD2I;   LGMD2L;   LGMD2N;   Actin Aggregation Myopathy;   Cap Disease;   Central Core Disease;   Centronuclear Myopathy;   Core Rod Myopathy;   Hyaline Body Myopathy;   Multiminicore Myopathy;   Myotubular Myopathy;   Nemaline Myopathy;   Tubular Aggregate Myopathy;   Zebra Body Disease Myopathy;   Congenital Myopathy Other;   Reducing Body Myopathy;   Sarcotubular Myopathy;   Spheroid Body Myopathy
Outcome Measure:
14 Recruiting Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders
Conditions: Anxiety Disorders;   Mood Disorders
Interventions: Behavioral: Single Diagnosis Treatment Protocol;   Behavioral: Unified Protocol (UP)
Outcome Measures: Anxiety Disorders Interview Schedule for DSM-IV-Lifetime Version;   Clinical Global Impression Severity (CGI-S) and Improvement Scales (CGI-I);   Structured Interview Guide for the Hamilton Anxiety and Depression Rating Scale (SIGH-A and SIGH-D);   Mini or Superlite-ADIS-IV;   Superlite-ADIS-IV;   Yale-Brown Obsessive Compulsive Scale Interview (Y-BOCS);   Panic Disorder Severity Scale (PDSS);   Liebowitz Social Anxiety Scale (LSAS);   Generalized Anxiety Disorder Severity Scale (GADSS);   Post-Traumatic Stress Disorder (PTSD) Symptom Scale-Interview Version (PSS-I);   Beck Depression Inventory (BDI-II);   Beck Anxiety Inventory (BAI);   Overall Anxiety Sensitivity and Impairment Scale (OASIS);   Work and Social Adjustment Scale (WSAS);   Credibility/Expectancy Questionnaire;   Rand-modified, Medical Outcomes Study 36-item Short-Form Health Survey (Rand-MOS-SF-36);   University of Rhode Island Change Assessment;   Homework Compliance Scale;   Anxiety Sensitivity Index;   Anxiety Control Questionnaire Revised (ACQ-R);   Behavioral Inhibition/Behavioral Activation Scale (BIS/BAS);   Eysenck Personality Questionnaire-Revised-Short Form (EPQR-S);   Emotion Regulation Questionnaire (ERQ);   Eysenck Personality Questionnaire-Revised - Short Form (EPQR-S)
15 Recruiting A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
Conditions: Alzheimer's Disease;   Dementia
Interventions: Drug: Drug: NIC5-15;   Drug: Placebo
Outcome Measures: Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)Score;   Change in Alzheimer's Disease Cooperative Study Clinician's Global Impression of Change (ADCS-CCGIC) Score;   Change in Mini-Mental State Examination (MMSE) Score;   Change in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Score;   Change in Neuropsychiatric Inventory (NPI) Score;   Changes in AD Biomarkers;   APO-E genotyping
16 Recruiting Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases
Conditions: Neurodegenerative Diseases;   Amyotrophic Lateral Sclerosis;   Multiple Sclerosis;   Parkinson Disease
Outcome Measure: Create a bank of fecal and blood samples for the future investigation of the microbial etiology and pathophysiology of neurodegenerative Diseases, including but not limited to amyotrophic lateral sclerosis, Parkinson's Diseases, and multiple sclerosis.
17 Unknown  Myocardial Microvascular Disease in ESRD
Conditions: End Stage Renal Disease;   Myocardial Microvascular Disease
Intervention: Procedure: Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire
Outcome Measures: Major cardiovascular events;   Incidence of myocardial microvascular Disease detected by FFR + CFR in ESRD patients with myocardial ischemia on non invasive tests.
18 Not yet recruiting Validation of DaTscan for Detection of Parkinson Disease Related Disorders
Conditions: Parkinson Disease;   Movement Disorders
Intervention: Drug: l-123 Ioflupane
Outcome Measure: Consistency Between Diagnostic Procedures
19 Recruiting Immune Regulation in Ulcerative Colitis or Crohn s Disease
Conditions: Crohn's Disease;   Inflammatory Bowel Disease;   Ulcerative Colitis
Outcome Measure:
20 Recruiting Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease.
Condition: "Alzheimer's Disease" and "Lewy Body Disease"
Interventions: Other: MRI;   Procedure: lumbar puncture;   Behavioral: neuropsychological tests
Outcome Measure: rate of alpha-synuclein in cerebrospinal fluid